Tuberculosis drug company TB Alliance revealed on Tuesday the addition of Jan Lundberg to its board of directors.
Dr Lundberg spent eight years as president of Lilly Research Laboratories and executive vice president of Science and Technology at Eli Lilly and Company.
Previously at AstraZeneca, Dr Lundberg was the global head of discovery research, including for infectious diseases and a TB Research facility in Bangalore.
Currently, Dr Lundberg is the cofounder of Aerocrine AB, a board member at Ardelyx, Betagenon and Image Analysis Group, a professor in the Department of Pharmacology at Karolinska Institute in Stockholm as well as a member of several governmental committees in both the EU and the US.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients